Per Persson CEO of Acarix invited to participate in Navigator's new interview series "Pejling"

Per Persson, CEO of Acarix recently participated in the Navigator's newly launched interview series "Pejling". The interview is based on discussions related to how the overall changing conditions, due to COVID -19, affect different industries and companies.

See the interview with Per Persson here>>

Navigator Pejling – Per Persson | VD Acarix

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.